Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
about
Memantine inhibits α3β2-nAChRs-mediated nitrergic neurogenic vasodilation in porcine basilar arteriesAmyloid-β-Induced Dysregulation of AMPA Receptor TraffickingNMDA Receptor Function During Senescence: Implication on Cognitive PerformancePharmacological Alternatives for the Treatment of Neurodegenerative Disorders: Wasp and Bee Venoms and Their Components as New Neuroactive ToolsShift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventionsEarly synaptic deficits in the APP/PS1 mouse model of Alzheimer's disease involve neuronal adenosine A2A receptors.Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylationDementia: timely diagnosis and early interventionGenetic variants in Alzheimer disease - molecular and brain network approachesWeight Loss in Patients with Dementia: Considering the Potential Impact of Pharmacotherapy.Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.Anticholinesterase-induced symptoms improved by pacemaker implantation in patients with Alzheimer's disease: analysis of 6 cases.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Alzheimer DiseaseDrug candidates in clinical trials for Alzheimer's disease.Developmental disability in the young and postoperative cognitive dysfunction in the elderly after anesthesia and surgery: do data justify changing clinical practice?The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesClinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity.NMDA-receptor activation but not ion flux is required for amyloid-beta induced synaptic depression.Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease.Evidence-based health care policy in reimbursement decisions: lessons from a series of six equivocal case-studies.Inhibition of the polyamine system counteracts β-amyloid peptide-induced memory impairment in mice: involvement of extrasynaptic NMDA receptors.Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysisEvaluation and management of the elderly patient presenting with cognitive complaints.Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease.Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review.False recognition in a mouse model of Alzheimer's disease: rescue with sensory restriction and memantine.Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementiaOPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE.Contribution of N-methyl-D-aspartate receptors to attention and episodic spatial memory during senescence.Calcium flux-independent NMDA receptor activity is required for Aβ oligomer-induced synaptic lossGlutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathologyPharmacological Treatment of Mild Cognitive Impairment as a Prodromal Syndrome of Alzheimer´s Disease.Memantine combined with environmental enrichment improves spatial memory and alleviates Alzheimer's disease-like pathology in senescence-accelerated prone-8 (SAMP8) mice.Use of memantine for the treatment of dementia.Neuronal receptors as targets for the action of amyloid-beta protein (Aβ) in the brain.The therapeutic potential of the endocannabinoid system for Alzheimer's disease.Protein misfolding in the late-onset neurodegenerative diseases: common themes and the unique case of amyotrophic lateral sclerosis.
P2860
Q21134148-A6DBA650-40CA-44B2-8F65-B1B50A99F381Q26748723-CCDFB24F-86C5-4B6E-97D1-3B8504027D21Q26770902-84FD7CEC-F7AD-4599-A111-FFD328CD207EQ26795786-8B2844DD-E434-49B5-B676-D9A3675EED49Q26830740-F398E647-77D0-4846-AEB9-9039A0A524EAQ27343149-4DA8D8FE-8DBE-4DDC-9400-C9545EC67535Q27499804-C1729129-AA7D-4AB5-832C-7BD53A6EC6E6Q28082444-42AADB25-3D6B-4CF9-A38E-C103ADD8FAB3Q28596011-8A08C66F-1DB7-4929-94B3-E421058F1DAFQ30234535-9A2AB05D-3631-415B-A6AF-E2D20DC21ED0Q30584897-A82EE288-5026-4897-8DF0-5F039E0FA000Q33161551-5C0BB4E4-4632-432A-B677-9131F2244007Q33165693-1390A993-B04A-4E03-9B7B-FE926C40414BQ33556068-63D62BFF-0A29-4760-BA0B-A1ECDA00EA0AQ33562441-AFB45F14-F413-4171-82BA-2F7A3EA1729BQ33916749-F3ABBD39-3056-4B7A-93FA-4E3A41905580Q34124787-6C039EE6-AAFA-4AE3-B12B-862C439A2D3DQ34329204-1BB5A378-157A-445E-97DF-0237EF71A365Q34408888-274B1D7F-04E5-44FC-B9B9-BF6A11F43E81Q34418562-3C50A605-9B7B-4E9D-8531-05BFA60B0AE2Q34764283-0EAEDD91-1B9D-4CD1-A9F6-58BD95844C2AQ35035648-4DBDF8A1-7A38-47DA-85F4-3D44A0A3E63CQ35036627-E9F7263D-ADF8-40B3-8268-D52E515CC532Q35186554-DA38329E-B1D8-46D8-B2ED-41586EF5EDBCQ35224319-AC038104-E739-4B60-9395-0F876579946DQ35447239-6E8D416D-C59C-48F1-BBA3-834409D26F0CQ35481827-CE1CB0C1-CAD2-4991-922C-5A6701637628Q36045044-8ACFA518-1886-4F1E-BC31-3602A05B659EQ36054180-A7ED68D8-79D9-47F0-9FB9-E2B17409101EQ36177038-FAEA7FD5-6E5D-4393-86C4-2347F32B7DFFQ36221014-67C888FA-AFAF-413D-AC76-1E21E9F8B303Q36289349-AB73A4EA-DF26-468E-931C-801293A56919Q36347364-79EC7D36-BDFA-466F-8CF1-B17357A2841EQ36485712-5DF5D821-7F58-4B6E-8170-62635CB58788Q36634130-B17FCCA9-ED7A-48ED-869C-47E82EC02F47Q36683174-9FB46A26-7A89-45CF-920B-859B70C81953Q37939987-3EFC1DB0-0E39-4630-901F-B2A34EE1A63BQ37977251-8B6F3266-9AF7-448C-BF4D-B52A228ABAEEQ37997020-5701EC63-180C-4228-945E-5BCAC25DC1ABQ38091029-A97BEFA2-9DAF-4DA7-92AF-E70859443BB9
P2860
Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
@ast
Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
@en
Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
@nl
type
label
Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
@ast
Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
@en
Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
@nl
prefLabel
Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
@ast
Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
@en
Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
@nl
P2093
P1433
P1476
Lack of evidence for the efficacy of memantine in mild Alzheimer disease
@en
P2093
Karen S Dagerman
Lon S Schneider
Rupert McShane
P304
P356
10.1001/ARCHNEUROL.2011.69
P577
2011-04-11T00:00:00Z